Federal Trade Commission Provisionally Accepts Consent Decree and Terminates Waiting Period for King Pharmaceuticals®, Inc.’s Acquisition of Alpharma Inc.

BRISTOL, Tenn. & BRIDGEWATER, N.J.--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (NYSE: KG) and Alpharma Inc. (NYSE: ALO) today announced that the U.S. Federal Trade Commission has provisionally accepted a proposed consent order for public comment and has terminated the Hart-Scott-Rodino waiting period applicable to King’s proposed acquisition of Alpharma.